RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
Renovaro (NASDAQ: RENB) announced that its subsidiary RenovaroCube has received grant funding approval for the Lumina project from the Eurostars funding program. The project, developed in collaboration with Flomics Biotech, Uppsala Universitet, and Oncodia, aims to create an advanced Minimal Residual Disease (MRD) detection platform for lung cancer using multi-omics biomarkers and AI technology.
The Eurostars program, co-funded by the European Union through Horizon Europe, provides over €250M in expected public-private investment annually for innovative SME projects. The Lumina platform targets a significant medical need, as 60% of curatively treated lung cancer patients experience relapse among the 5.7 million lung cancer cases monitored globally each year. The project combines liquid biopsies with multi-omics biomarker technology to provide non-invasive, accurate disease detection.
Renovaro (NASDAQ: RENB) ha annunciato che la sua controllata RenovaroCube ha ricevuto l'approvazione per il finanziamento del progetto Lumina dal programma di finanziamento Eurostars. Il progetto, sviluppato in collaborazione con Flomics Biotech, Uppsala Universitet e Oncodia, mira a creare una piattaforma avanzata per la rilevazione della Malattia Residua Minima (MRD) nel cancro ai polmoni utilizzando biomarcatori multi-omici e tecnologia AI.
Il programma Eurostars, co-finanziato dall'Unione Europea attraverso Horizon Europe, prevede oltre 250 milioni di euro in investimenti pubblici e privati attesi annualmente per progetti innovativi delle PMI. La piattaforma Lumina punta a soddisfare un'importante esigenza medica, poiché il 60% dei pazienti affetti da cancro ai polmoni curati sperimentano una recidiva tra i 5,7 milioni di casi di cancro ai polmoni monitorati a livello globale ogni anno. Il progetto combina biopsis liquide con tecnologia biomarker multi-omici per fornire una rilevazione della malattia non invasiva e accurata.
Renovaro (NASDAQ: RENB) anunció que su subsidiaria RenovaroCube ha recibido la aprobación de financiamiento para el proyecto Lumina del programa de financiamiento Eurostars. El proyecto, desarrollado en colaboración con Flomics Biotech, Uppsala Universitet y Oncodia, tiene como objetivo crear una plataforma avanzada para la detección de Enfermedad Residual Mínima (MRD) en cáncer de pulmón utilizando biomarcadores multi-ómicos y tecnología de IA.
El programa Eurostars, cofinanciado por la Unión Europea a través de Horizon Europe, proporciona más de 250 millones de euros en inversiones públicas y privadas esperadas anualmente para proyectos innovadores de PYMEs. La plataforma Lumina se dirige a una necesidad médica significativa, ya que el 60% de los pacientes con cáncer de pulmón tratados curativamente experimentan recaídas entre los 5,7 millones de casos de cáncer de pulmón monitoreados a nivel mundial cada año. El proyecto combina biopsias líquidas con tecnología de biomarcadores multi-ómicos para proporcionar una detección de la enfermedad no invasiva y precisa.
레노바로 (NASDAQ: RENB)는 그 자회사 레노바로큐브가 유로스타 프로그램의 루미나 프로젝트에 대한 보조금 자금 승인 소식을 발표했습니다. 이 프로젝트는 Flomics Biotech, Uppsala Universitet, Oncodia와 협력하여 개발되었으며, 멀티 오믹스 바이오마커와 AI 기술을 사용하여 폐암에 대한 최소 잔여 질병(MRD) 탐지 플랫폼을 구축하는 것을 목표로 합니다.
유로스타 프로그램은 Horizon Europe을 통해 유럽연합이 공동 자금 지원하며 매년 혁신적인 중소기업 프로젝트에 대해 2억 5천만 유로 이상의 공공 및 민간 투자 부문을 제공합니다. 루미나 플랫폼은 상당한 의료적 요구를 해결하기 위해 설계되었으며, 치료를 받은 폐암 환자의 60%가 재발을 경험하는데, 이는 매년 전 세계적으로 570만 건의 폐암 사례가 모니터링되고 있습니다. 이 프로젝트는 액체 생검과 멀티 오믹스 바이오마커 기술을 결합하여 비침습적이고 정확한 질병 탐지를 제공합니다.
Renovaro (NASDAQ: RENB) a annoncé que sa filiale RenovaroCube a reçu l'approbation pour le financement du projet Lumina dans le cadre du programme de financement Eurostars. Le projet, développé en collaboration avec Flomics Biotech, l'Université d'Uppsala et Oncodia, vise à créer une plateforme avancée pour la detection de la Maladie Résiduelle Minime (MRD) dans le cancer du poumon en utilisant des biomarqueurs multi-omiques et la technologie d'IA.
Le programme Eurostars, cofinancé par l'Union européenne à travers Horizon Europe, prévoit plus de 250 millions d'euros d'investissements public-privé attendus chaque année pour des projets innovants de PME. La plateforme Lumina répond à un besoin médical significatif, puisque 60 % des patients atteints de cancer du poumon traités curativement présentent des récidives parmi les 5,7 millions de cas de cancer du poumon surveillés dans le monde chaque année. Le projet combine des biopsies liquides avec la technologie des biomarqueurs multi-omiques pour fournir une détection non invasive et précise de la maladie.
Renovaro (NASDAQ: RENB) gab bekannt, dass ihre Tochtergesellschaft RenovaroCube die Genehmigung für eine Fördermittelzusage für das Lumina-Projekt im Rahmen des Eurostars-Finanzierungsprogramms erhalten hat. Das Projekt, das in Kooperation mit Flomics Biotech, der Uppsala Universität und Oncodia entwickelt wurde, zielt darauf ab, eine fortschrittliche Plattform zur Erkennung der Minimalen Restkrankheit (MRD) bei Lungenkrebs mithilfe von multi-omischen Biomarkern und KI-Technologie zu schaffen.
Das Eurostars-Programm, das co-finanziert wird von der Europäischen Union durch Horizon Europe, bietet jährlich über 250 Millionen Euro an erwarteten öffentlich-privaten Investitionen für innovative KMU-Projekte. Die Lumina-Plattform richtet sich an ein erhebliches medizinisches Bedürfnis, da 60% der kurativ behandelten Lungenkrebspatienten einen Rückfall erleben von den jährlich weltweit überwachten 5,7 Millionen Lungenkrebserkrankungen. Das Projekt kombiniert flüssige Biopsien mit multi-omischen Biomarker-Technologien für eine nicht-invasive, präzise Krankheitsdiagnose.
- Secured EU funding through prestigious Eurostars program
- Addresses large market opportunity with 5.7 million lung cancer cases globally
- Partnership with established institutions strengthens project credibility
- None.
Insights
LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI
LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary RenovaroCube (the ‘Cube’), a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, together with its consortium partners Flomics Biotech, Uppsala Universitet and Oncodia, received grant funding approval for the Lumina project from the Eurostars funding program after review by an independent expert panel.
Eurostars is part of the European Partnership on Innovative SMEs (Small and Medium-sized Enterprises). The partnership is co-funded by the European Union through Horizon Europe. Eurostars is the largest international funding program for SMEs wishing to collaborate on R&D projects that create innovative products, processes or services for commercialization, with over
The Lumina project aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. Harnessing the power of multi-omics biomarkers and AI-driven technology, this platform aims to transform recurrence risk prediction and treatment strategies for millions of patients worldwide.
“This award further validates our purpose-built AI platform in facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization,” said David Weinstein, Chief Executive Officer of Renovaro. “In partnership with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech, the Lumina project is focused on improving lung cancer patient survival. Over 5.7 million lung cancer cases are treated or monitored globally each year, and of all curatively treated lung cancer patients,
A High-Performance Platform for Better Outcomes
The objective of the LUMINA project is to develop a cutting-edge platform designed to provide unparalleled accuracy in detecting minimal residual disease. To achieve this, liquid biopsies combined with multi-omics biomarker technology, represent a revolutionary approach. The LUMINA project’s AI-powered platform capitalizes on this potential, aiming to provide a highly accurate, non-invasive solution that addresses a critical unmet need in lung cancer care.
Collaborative Expertise
The LUMINA project is built on a strong foundation of collaboration with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech. These partnerships bring together world-class clinical expertise and a multi-omic approach, leveraging the analysis of cell-free DNA and RNA to ensure the platform’s success.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
About RenovaroCube
RenovaroCube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data for early detection of diseases based on non-invasive testing using liquid biopsy (blood).
RenovaroCube’s AI platform is purpose-built to process and analyze multi-omic molecular data, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally developed for the fintech sector, this platform is being reengineered for healthcare, offering:
- Sequence Processing: Transform raw molecular data from patient samples into clean, analyzable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
- Biomarker Discovery: Harness unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
- AI Factory: Employ sophisticated machine learning models to predict cancer presence, origin, and stage based on extracted biomarker features. These models are trained on vast datasets to enhance accuracy and reliability, supporting early detection and personalized treatment strategies.
- Precision Diagnostics: Offer an interactive interface for visualizing data, generating comprehensive clinical reports, and delivering actionable insights across various omic layers and biomarkers. This interface empowers healthcare professionals to make informed decisions with confidence.
About Flomics Biotech, S.L.
Flomics https://www.flomics.com/ is a fast-growing biotech company based in Barcelona, operating in the genomics and liquid biopsy space. Flomics’ objective is to develop a revolutionary diagnostic blood test based on Next-Generation Sequencing (NGS) of cell-free RNA, suitable for the early detection of different complex diseases, in particular cancer. Additionally, as CRO, Flomics also offers the following services: biomarker discovery (on tissue and biofluids), support on bioinformatic analysis and an intuitive web-based platform suitable for the analysis of NGS data (Stratus). The team at Flomics has a strong background in RNA and liquid biopsy, as well as advanced bioinformatics analysis methods.
About Uppsala Universitet
Uppsala University is the first university in the Nordic countries and a world-class research institution. The Department of Immunology, Genetics and Pathology is dedicated to advancing cancer diagnostics and treatment through the study of molecular changes associated with cancer. The research aims to harness measurable molecular information to improve diagnosis and therapy, with a strong focus on developing liquid biopsy-based diagnostic tests. A key initiative is the U-CAN project, which provides a unique biobank of high-quality clinical samples and data from cancer patients to support translational research. This effort, combined with cutting-edge molecular biology and clinical expertise, underscores the university's commitment to transforming cancer care.
About Oncodia AB
Oncodia is an innovative Medical Technology company based in Uppsala, Sweden. Oncodia is committed to providing in vitro diagnostic products that consistently meet customer needs, enhance patient treatment outcomes and adhere to regulatory and statutory requirements. Oncodia provides CE/IVD software for precision cancer medicine as well as CE/IVD products for DNA/RNA isolation from diagnostic tissue specimens. Their focus is to supply clinical pathology and oncology with the right solutions for optimal molecular diagnostics of solid tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com and STarsh@Renovarogroup.com
FAQ
What is the Lumina project that RENB received funding for?
How much funding does the Eurostars program provide annually?
What is the market opportunity for RENB's Lumina platform in lung cancer?
Who are RENB's partners in the Lumina project?
What technology does RENB's Lumina platform use for cancer detection?
